期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 29, 期 3, 页码 326-331出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2022.10.022
关键词
Antibiotic resistance; Azithromycin; Childhood mortality; Infectious disease; Mass drug administration
The World Health Organization recommends mass drug administration (MDA) of azithromycin to reduce childhood mortality in high-risk areas. While concerns about antibiotic resistance exist, MDA falls within a justifiable range compared to other uses of antibiotics. Efforts should be made to improve monitoring and data collection to inform decisions about MDA and antibiotic resistance.
Background: WHO recommends mass drug administration (MDA) of the antibiotic azithromycin for children aged 1-11 months in areas with high rates of infant and child mortality. Notwithstanding the substantial potential benefits of lowering childhood mortality, MDA raises understandable concerns about exacerbating antibiotic resistance. Objectives: In this study, we aimed to evaluate the use of MDA using both quantitative and ethical considerations.Sources: We performed a series of literature searches between July 2019 and June 2022. Content: We first compared MDA with other uses of antibiotics using the standard metric of 'number needed to treat', and five additional criteria: (1) other widely accepted uses of anti-infectives (2) absolute use (i.e. total number), of antibiotics, (3) risk-benefit trade-off, (4) availability of short-term alternatives, and (5) the precedent for implementing similar interventions. We found that MDA falls well within a justifiable range when compared with widely accepted uses of antibiotics in terms of the number needed to treat. The other five criteria we considered provided further support for the use of MDA to prevent childhood mortality.Implications: Although better data on antibiotic use and resistance are needed, efforts to reduce antibiotic use and resistance should not start with halting MDA of azithromycin in the areas with the highest rates of childhood mortality. Improving data to inform this decision is critical. However, on the basis of the best evidence available, we believe that concerns regarding resistance should not thwart MDA; instead, MDA should be accompanied by robust plans to monitor its efficacy and changes in resistance levels. Similar considerations could be included in a framework for evaluating the benefits of antibiotics against the risk of resistance in other contexts. Rebecca Kahn, Clin Microbiol Infect 2023;29:326 (c) 2022 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据